Oral azacitidine maintenance has manageable safety profile in AML patients in first CR/CRiSeptember 26, 2021AML
Low-dose cytarabine+cladribine improves outcomes in elderly AML patients unfit for intensive chemotherapySeptember 26, 2021AML
GO vs. non-GO therapy offers better survival but with higher toxicity in AML and high-risk MDSSeptember 26, 2021AML
Enasidenib vs. standard of care therapies prolongs survival in patients with R/R AML with IDH2 mutationSeptember 26, 2021AML
No benefits of decitabine+sapacitabine over decitabine monotherapy in older patients with newly diagnosed AMLSeptember 26, 2021AML
Survival benefit with high-intensity chemotherapy followed by second allo-SCT or DLI in AML relapse after allo-SCTAugust 29, 2021AML
High-risk AML: Induction chemotherapy with ID-AraC followed by allo-HSCT improves survival August 29, 2021AML
